NuFund Venture Group β Full Portfolio
5 tracked investments Β· listed companies and verified rows first
Duo Oncology is a clinical-stage company developing tumor-activated prodrug combinations intended to replace toxic multi-agent chemotherapy with single medicines that concentrate activity in tumors.
BiotechHealthtechPittsburgh, US
SONG LI(Director, Promoter)JING-ZHOU HOU(Executive Officer, Director, Promoter)Sam Rothstein(CEO & Cofounder)inKatherine Eichinger(Chief Operating Officer)STEPHEN THORNE(Executive Officer, Promoter)
BoardJOE GATTO(Director)in
Co-investorsUlu VenturesInnovation WorksNuFund
CARI Health develops diagnostic solutions for medication monitoring, specifically focused on personalized methadone dosing for opioid use disorder treatment.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Patrik Schmidle(Chief Executive Officer)
BoardGioia Messinger(Director)Charles Patton(Director)
Co-investorsCove Fund
Resolute Science appears to be a clinical-stage therapeutics company focused on oncology and cancer treatment development.
BiotechDigital HealthMedical DevicesSan Diego, US
Faith Barnett(Executive Officer, Director)inAndre Basbaum(Executive Officer, Director)
BoardJames Mackay(Director)
Trio Pharmaceuticals develops dual-targeting antibody drugs to treat cancer, using its TIE-ADC and TRAILBody platforms to kill cancer cells and overcome tumor immunosuppression while reducing treatment-related toxicity.
BiotechHealthtechSan Diego, US
H. Kim Lyerly(CMO & Founder)inReiner Laus(Executive Officer, Director)Shivarupam Bhowmik(Executive Officer, Director)Jeffrey Friedman(Director)
VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity.
BiotechHealthtechMedical DevicesBethesda, US
JOSHUA WANG(Executive Officer, Director, Promoter)inJOHN TROYER(Executive Officer)
BoardCYNTHIA POH(Director)KEVIN KOH RONGSHENG(Director)HAOLIN SUNG(Director)inCHE HSU(Director)in
Co-investorsMaryland TEDCOUlu VenturesGaingelsMana Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.